Dense Breasts: Imaging Guidelines Need Update, Experts Say

The landscape of breast cancer screening is evolving, particularly for women with dense breasts. Current guidelines regarding supplemental imaging are under scrutiny, with experts calling for updates in light of emerging research. A key area of focus is whether magnetic resonance imaging, or MRI, can reduce breast cancer deaths in high-risk groups.

Understanding Breast Density and Screening Challenges

Breast density refers to the proportion of fibrous and glandular tissue compared to fatty tissue in the breasts. Women with dense breasts have more fibrous and glandular tissue, which can make it harder to detect tumors on a mammogram. Dense tissue appears white on a mammogram, and so do many breast cancers. This can obscure small tumors, potentially leading to delayed diagnosis. The FDA issued a national requirement in March 2023 for dense breast reporting to patients and their referring providers, aiming to increase awareness and informed decision-making. The American College of Radiology provides resources on supplemental screening based on breast density.

Traditionally, mammography has been the standard screening method. However, for women with dense breasts, supplemental screening options are often considered. These include ultrasound, MRI, and digital breast tomosynthesis (DBT), also known as 3D mammography. The challenge lies in determining which supplemental screening method is most effective and appropriate for different risk levels.

New Evidence Points to MRI’s Potential

While the specific details of the new study prompting the expert reaction weren’t detailed in the source material, the consensus is that it reinforces the potential benefits of MRI as a supplemental screening tool, particularly for women with extremely dense breasts. Moffitt Cancer Center reports that for those with extremely dense breasts, a panel recommends starting supplemental breast MRI screening at age 50, with consideration given to earlier initiation for some individuals.

MRI is a highly sensitive imaging technique that uses magnetic fields and radio waves to create detailed images of the breast. It doesn’t use ionizing radiation, unlike mammography and DBT. However, MRI can be more expensive and time-consuming than other screening methods, and it can also have a higher rate of false-positive results, leading to unnecessary biopsies.

USPSTF Recommendations and Ongoing Research

The U.S. Preventive Services Task Force (USPSTF) recently updated its recommendations on breast cancer screening in April 2024, recommending that all women get screened every other year starting at age 40. The USPSTF also highlighted the require for more research on screening strategies for women with dense breasts. The Task Force acknowledges that current evidence is insufficient to provide definitive guidance on the optimal approach for this population.

The USPSTF’s call for further research underscores the complexity of the issue. Studies are needed to determine the optimal timing, frequency, and modality of supplemental screening for women with dense breasts, taking into account individual risk factors and preferences. Research is also crucial to address health disparities in breast cancer screening and treatment experienced by various racial and ethnic groups.

What Does “Average Risk” Mean?

The supplemental screening guidelines often categorize women by risk level. “Average risk” generally refers to women without a personal or strong family history of breast cancer, no known genetic mutations that increase risk, and no prior chest radiation therapy. However, even within the “average risk” category, breast density plays a significant role in determining the need for supplemental screening. The guidelines outlined in the ACR document differentiate between average risk with nondense, heterogeneously dense, and extremely dense breasts, recommending different approaches to supplemental screening for each category.

Navigating Supplemental Screening Options

The ACR document details appropriateness categories for various screening procedures. For women with average risk and nondense breasts, digital breast tomosynthesis is usually appropriate, while ultrasound and MRI are usually not. However, as breast density increases to heterogeneously dense or extremely dense, the appropriateness of ultrasound and MRI shifts to “may be appropriate.” It’s important to note that these are guidelines, and individual decisions should be made in consultation with a healthcare provider.

The choice of supplemental screening method should be individualized based on a woman’s risk factors, breast density, personal preferences, and access to resources. Factors to consider include the potential benefits and harms of each method, the cost, and the availability of qualified radiologists to interpret the images.

What Comes Next: A Process of Refinement

The evolving understanding of breast density and screening necessitates a continuous process of refinement. Ongoing research, coupled with careful evaluation of real-world outcomes, will be essential to optimize screening strategies and reduce breast cancer mortality. Expect to see continued debate and adjustments to guidelines as new evidence emerges. Healthcare providers will need to stay informed about the latest recommendations and engage in shared decision-making with their patients. The focus will likely remain on personalized screening approaches that balance the benefits of early detection with the potential harms of overdiagnosis and overtreatment.